{"denoms":[{"counts":[{"groupId":"BG000","value":"402"},{"groupId":"BG001","value":"402"},{"groupId":"BG002","value":"100"},{"groupId":"BG003","value":"103"},{"groupId":"BG004","value":"1007"}],"units":"Participants"}],"groups":[{"description":"XP=cisplatin+capecitabine and FP=cisplatin+5-fluorouracil. Neoadjuvant: Prior to surgery, participants received 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\\^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m\\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.\n\nAdjuvant: 4 to 10 weeks post-surgery, participants received 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles.","id":"BG000","title":"Pembrolizumab + XP/FP"},{"description":"Neoadjuvant: Prior to surgery, participants received 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.\n\nAdjuvant: 4 to 10 weeks post-surgery, participants received 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m\\^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m\\^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m\\^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles.","id":"BG001","title":"Placebo + XP/FP"},{"description":"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants received 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\\^2 via IV infusion, oxaliplatin 85 mg/m\\^2 via IV infusion, 5FU 2600 mg/m\\^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m\\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).\n\nAdjuvant: 4 to 10 weeks post-surgery, participants received 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m\\^2, oxaliplatin 85 mg/m\\^2, 5FU 2600 mg/m\\^2, and leucovorin 200 mg/m\\^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles.","id":"BG002","title":"Pembrolizumab + FLOT Cohort"},{"description":"Neoadjuvant: Prior to surgery, participants received 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\\^2 via IV infusion, oxaliplatin 85 mg/m\\^2 via IV infusion, 5FU 2600 mg/m\\^2 via IV infusion, and leucovorin 200 mg/m\\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).\n\nAdjuvant: 4 to 10 weeks post-surgery, participants received 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m\\^2 via IV infusion, oxaliplatin 85 mg/m\\^2 via IV infusion, 5FU 2600 mg/m\\^2 via IV infusion, and leucovorin 200 mg/m\\^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles.","id":"BG003","title":"Placebo + FLOT Cohort"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"221"},{"groupId":"BG002","value":"58"},{"groupId":"BG003","value":"64"},{"groupId":"BG004","value":"550"}],"title":"Adults (between 18 and 64 years)"},{"measurements":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"456"}],"title":"From 65 to 84 years"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"85 years and older"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"114"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"283"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"288"},{"groupId":"BG001","value":"287"},{"groupId":"BG002","value":"78"},{"groupId":"BG003","value":"71"},{"groupId":"BG004","value":"724"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"118"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"333"},{"groupId":"BG001","value":"323"},{"groupId":"BG002","value":"89"},{"groupId":"BG003","value":"94"},{"groupId":"BG004","value":"839"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"50"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"193"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"395"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"11"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"178"},{"groupId":"BG001","value":"174"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"97"},{"groupId":"BG004","value":"541"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"14"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"45"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"191"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"387"}],"title":"Asia"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"25"}],"title":"US"},{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"56"},{"groupId":"BG003","value":"70"},{"groupId":"BG004","value":"325"}],"title":"Western Europe"},{"measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"270"}],"title":"ROW"}]}],"description":"Participants were categorized according to geographic region of site: Asia, Western Europe, United States (US), and Rest of World (ROW).","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"31"},{"groupId":"BG004","value":"215"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"302"},{"groupId":"BG001","value":"306"},{"groupId":"BG002","value":"74"},{"groupId":"BG003","value":"66"},{"groupId":"BG004","value":"748"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"43"}],"title":"Stage IVa"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Missing"}]}],"description":"Participants were categorized by tumor stage based on American Joint Committee on Cancer (AJCC) staging guidelines. The lower the cancer stage, the less the cancer has spread. Stages can range from I to IVd. 'a' describes less aggressive (slower growing) cancer, while 'd' describes more aggressive (faster growing) cancer within a numeric stage.","paramType":"COUNT_OF_PARTICIPANTS","title":"Tumor Staging","unitOfMeasure":"Participants"}]}